$0.03
0.00% yesterday
Nasdaq, Nov 15, 04:17 pm CET
ISIN
US0076242082
Symbol
ADXS
Sector
Industry

Advaxis, Inc. Stock price

$0.03
+0.00 0.00% 1M
-0.16 85.79% 6M
-0.64 95.95% YTD
-0.86 96.97% 1Y
-32.65 99.92% 3Y
-31.89 99.92% 5Y
-3,563.97 100.00% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
+0.00 0.00%
ISIN
US0076242082
Symbol
ADXS
Sector
Industry

Key metrics

Market capitalization $1.15m
Enterprise Value $-4.50m
EV/Sales (TTM) EV/Sales -450.00
P/S ratio (TTM) P/S ratio 115.00
Revenue growth (TTM) Revenue growth -97.40%
Revenue (TTM) Revenue $10.00k
EBIT (operating result TTM) EBIT $-29.42m
Cash position $7.19m
EPS (TTM) EPS $-9.85
Short interest 1.35%
Show more

Is Advaxis, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Advaxis, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Advaxis, Inc.:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Advaxis, Inc.:

Hold
100%

Financial data from Advaxis, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '23
+/-
%
0.01 0.01
-
100%
- Direct Costs 0.14 0.14
-
1,400%
- -
-
-
- Selling and Administrative Expenses 12 12
-
118,300%
- Research and Development Expense 17 17
-
174,700%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -29 -29
-
-294,170%
Net Profit -28 -28
-
-276,100%

In millions USD.

Don't miss a Thing! We will send you all news about Advaxis, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. It has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.

Head office United States
CEO Ken Berlin
Founded 2017
Website www.ayalapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today